Publications by authors named "Mana Aizawa"
Article Synopsis
- Vepdegestrant (ARV-471) is an oral drug designed to degrade the estrogen receptor, specifically targeting Japanese patients with advanced ER+/HER2- breast cancer who are resistant to standard treatments.
- In a phase 1 study involving six female patients, the drug was administered at a daily dose of 200 mg, with findings showing no dose-limiting toxicities and a mean treatment duration of 9.8 weeks; most patients tolerated the treatment well, experiencing only mild adverse events.
- The pharmacokinetic data suggested similar drug absorption profiles between Japanese and Western patients, and two patients showed stable disease after 24 weeks of treatment, indicating some potential for clinical benefit.
Article Synopsis
- The phase 3 JAVELIN Renal 101 trial showed that first-line treatment with avelumab plus axitinib improves objective response rate (ORR) and progression-free survival (PFS) in patients with advanced renal cell carcinoma (aRCC) compared to sunitinib.
- A retrospective study in Japan analyzed clinical data from 48 aRCC patients treated with avelumab plus axitinib, revealing a 48.8% ORR and a median PFS of 15.3 months, with a median follow-up of 10.4 months.
- The study found that 50% of patients were still on treatment at the cutoff, and the
Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed CP-CML. The minimum follow-up period was 3 years and median duration of treatment was 35.
View Article and Find Full Text PDFIntroduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types; axitinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We report the final analysis from VEGF Liver 100 (NCT03289533), a phase 1b study evaluating safety and efficacy of avelumab plus axitinib in treatment-naive patients with aHCC.
View Article and Find Full Text PDF